“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

Array BioPharma


Array BioPharma products

BRAFTOVI (encorafenib) + MEKTOVI (binimetinib)
Indication: BRAF V600E/V600K unresectable or metastatic melanoma—first approved as a combination therapy; being studied in a targeted triplet regimen for BRAF-mutant metastatic colorectal cancer as part of Array’s core oncology franchise

Additionally, Array has been instrumental in discovering or developing the following impactful oncology agents—each subsequently licensed or approved by partner organizations under different brand names:

  • KRAZATI (adagrasib) – KRAS G12C inhibitor

  • TUKYSA (tucatinib) – HER2-targeted therapy

  • KOSELUGO (selumetinib) – MEK1/2 inhibitor

  • VITRAKVI (larotrectinib) – TRK fusion inhibitor

  • RETEVMO (selpercatinib) – RET inhibitor

  • GANOVO (danoprevir) – HCV protease inhibitor (approved in China)

Array also advanced several clinical-stage pipeline candidates prior to acquisition, including:

  • Filanesib (ARRY-520) – KSP inhibitor investigated in multiple myeloma

  • ARRY-797 – p38 inhibitor explored in LMNA-related dilated cardiomyopathy

Array was acquired by Pfizer in mid-2019 and folded into its Oncology R&D infrastructure, significantly enhancing Pfizer’s targeted small-molecule cancer portfolio.



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)